Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity

Biochemical and Biophysical Research Communications

Volumn 430, Issue 3, 2013, Pages 963-968

  Lasagna Reeves, Cristian A ^a,b   Clos, Audra L ^a   Castillo Carranza, Diana ^a   Sengupta, Urmi ^a   Guerrero Muñoz, Marcos ^a   Kelly, Brent ^a   Wagner, Richard ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer: Basal Cell Carcinoma; Fibrils; Oligomers; P53

Indexed keywords

AMYLOID; OLIGOMER; PROTEIN P53;

ARTICLE; ATOMIC FORCE MICROSCOPY; BASAL CELL CARCINOMA; CARCINOGENESIS; CELL CULTURE; CLINICAL ARTICLE; CYTOTOXICITY; FIBER; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DNA BINDING;

AMYLOID; APOPTOSIS; CARCINOMA, BASAL CELL; CELL LINE, TUMOR; DNA; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872490673     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.130     Document Type: Article

References (26)

1. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. P53 mutations in human cancers. Science 1991, 253:49-53.
2. Bullock A.N., Fersht A.R. Rescuing the function of mutant p53. Nat. Rev. Cancer 2001, 1:68-76.
3. Moll U.M., Ostermeyer A.G., Haladay R., Winkfield B., Frazier M., Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 1996, 16:1126-1137.
4. Ostermeyer A.G., Runko E., Winkfield B., Ahn B., Moll U.M. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. USA 1996, 93:15190-15194.
5. Wolff A., Technau A., Ihling C., Technau-Ihling K., Erber R., Bosch F.X., Brandner G. Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. Oncogene 2001, 20:1307-1317.
6. Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. (Berl) 2003, 81:678-699.
7. Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75:333-366.
8. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer 2007, 6:1.
9. Comenzo R.L. Amyloidosis. Curr. Treat. Options Oncol. 2006, 7:225-236.
10. Malle E., Sodin-Semrl S., Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci. 2009, 66:9-26.
11. Weedon D., Shand E. Amyloid in basal cell carcinomas. Br. J. Dermatol. 1979, 101:141-146.
12. Rigacci S., Bucciantini M., Relini A., Pesce A., Gliozzi A., Berti A., Stefani M. The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys. J. 2008, 94:3635-3646.
13. Hegde R.S., Tremblay P., Groth D., DeArmond S.J., Prusiner S.B., Lingappa V.R. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999, 402:822-826.
14. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., Lambrechts D., Suh Y.A., Rousseau F., Schymkowitz J. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
15. Ano Bom A.P., Rangel L.P., Costa D.C., de Oliveira G.A., Sanches D., Braga C.A., Gava L.M., Ramos C.H., Cepeda A.O., Stumbo A.C., De Moura Gallo C.V., Cordeiro Y., Silva J.L. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J. Biol. Chem. 2012, 287:28152-28162.
16. Mahmoud S.F., Azadeh B. Basal cell carcinoma in Qatar. Int. J. Dermatol. 1996, 35:704-706.
17. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
18. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007, 2:18.
19. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999, 309:274-284.
20. Nie C.L., Wei Y., Chen X., Liu Y.Y., Dui W., Liu Y., Davies M.C., Tendler S.J., He R.G. Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. PLoS One 2007, 2:e629.
21. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
22. Luibl V., Isas J.M., Kayed R., Glabe C.G., Langen R., Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J. Clin. Invest. 2006, 116:378-385.
23. Nieva J., Song B.D., Rogel J.K., Kujawara D., Altobel L., Izharrudin A., Boldt G.E., Grover R.K., Wentworth A.D., Wentworth P. Cholesterol secosterol aldehydes induce amyloidogenesis and dysfunction of wild-type tumor protein p53. Chem. Biol. 2011, 18:920-927.
24. Kaganovich D., Kopito R., Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature 2008, 454:1088-1095.
25. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflamm. 2004, 1:24.
26. Butler J.S., Loh S.N. Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochem. 2003, 42:2396-2403.